C4X Stock Overview
A clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Valerio Therapeutics Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.075 |
| 52 Week High | €0.17 |
| 52 Week Low | €0.061 |
| Beta | 1.73 |
| 1 Month Change | -1.44% |
| 3 Month Change | 9.93% |
| 1 Year Change | -54.36% |
| 3 Year Change | -82.22% |
| 5 Year Change | -85.35% |
| Change since IPO | -99.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| C4X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.6% | -2.9% | -2.6% |
| 1Y | -54.4% | -14.7% | 6.9% |
Return vs Industry: C4X underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: C4X underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| C4X volatility | |
|---|---|
| C4X Average Weekly Movement | 21.6% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C4X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: C4X's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 38 | Julien Miara | valeriotx.com |
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer, as well as in phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children.
Valerio Therapeutics Société anonyme Fundamentals Summary
| C4X fundamental statistics | |
|---|---|
| Market cap | €11.70m |
| Earnings (TTM) | -€19.66m |
| Revenue (TTM) | €1.89m |
6.2x
P/S Ratio-0.6x
P/E RatioIs C4X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C4X income statement (TTM) | |
|---|---|
| Revenue | €1.89m |
| Cost of Revenue | €477.00k |
| Gross Profit | €1.41m |
| Other Expenses | €21.07m |
| Earnings | -€19.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 74.75% |
| Net Profit Margin | -1,040.66% |
| Debt/Equity Ratio | 317.0% |
How did C4X perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 17:55 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Valerio Therapeutics Société anonyme is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stéphan Dubosq | Arkeon Finance |
| Eric Le Berrigaud | Bryan Garnier & Co |
| Arsene Guekam | CIC Market Solutions (ESN) |